Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy

Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing

NCT01819168 ·Status: COMPLETED

Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.

NCT01282840 ·Status: COMPLETED ·Phase: NA

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

NCT06197295 ·Status: RECRUITING ·Phase: PHASE4

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285 ·Status: COMPLETED ·Phase: PHASE4

Predictors for Retreatement of OAB After DC Mirabegron

NCT04550702 ·Status: COMPLETED

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345 ·Status: TERMINATED

Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes

NCT07025642 ·Status: RECRUITING ·Phase: NA

Sexual Function Trial of Overactive Bladder: Medication Versus PTNS

NCT03500146 ·Status: COMPLETED

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

NCT03175029 ·Status: COMPLETED ·Phase: PHASE2

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01043666 ·Status: COMPLETED ·Phase: PHASE3

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

NCT01223937 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder

NCT00780832 ·Status: TERMINATED ·Phase: NA

Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study

NCT04412876 ·Status: WITHDRAWN ·Phase: PHASE3

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

NCT03251300 ·Status: UNKNOWN ·Phase: PHASE4

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

NCT07025044 ·Status: RECRUITING

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

NCT04023253 ·Status: UNKNOWN ·Phase: PHASE3

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

NCT03572231 ·Status: COMPLETED

TPTNS: Home vs Hospital Treatment for Overactive Bladder

NCT03727711 ·Status: UNKNOWN ·Phase: NA

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

NCT03566134 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

NCT02485067 ·Status: COMPLETED ·Phase: PHASE3

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

NCT00231790 ·Status: COMPLETED ·Phase: PHASE2

Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women

NCT03807024 ·Status: COMPLETED

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

NCT01868516 ·Status: COMPLETED ·Phase: PHASE2

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

NCT03602508 ·Status: COMPLETED

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

NCT05946902 ·Status: UNKNOWN ·Phase: PHASE4